Article
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology - 1 Feb 2011
McClay Joseph L, Adkins Daniel E, Aberg Karolina, Bukszár Jozsef, Khachane Amit N, Keefe Richard S E, Perkins Diana O, McEvoy Joseph P, Stroup T Scott, Vann Robert E, Beardsley Patrick M, Lieberman Jeffrey A, Sullivan Patrick F, van den Oord Edwin J C G
Abstract excerpt
Neurocognitive deficits are a core feature of schizophrenia and, therefore, represent potentially critical outcome variables for assessing antipsychotic treatment response. We performed genome-wide association studies (GWAS) with 492K single nucleotide polymorphisms (SNPs) in a sample of 738 patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness study. Outcome variables...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.